Compare Alcon AG (ALC) vs Rex Fang & Innovation Equity Premium Income ETF (FEPI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Rex Fang & Innovation Equity Premium Income ETF — how do they compare? Alcon AG trades at $66.8 (market cap $32.69B), while Rex Fang & Innovation Equity Premium Income ETF trades at $41.73. The key difference: Alcon AG pays a 0.54% dividend while Rex Fang & Innovation Equity Premium Income ETF pays none, and Rex Fang & Innovation Equity Premium Income ETF is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | FEPI | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $92.22 | $49.54 |
52-Week Low | $62.02 | $38.13 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
FEPI (REX FANG & Innovation Equity Premium Income ETF) trades at $42.53, up 1.5% with a bearish technical signal. The ETF employs a covered call strategy on concentrated tech holdings, generating high weekly dividends but facing NAV erosion concerns. Recent transition to weekly distributions aims to enhance income appeal, though technical indicators show selling pressure outweighing buying signals.
The outlook balances high yield appeal against structural limitations. The 25% dividend yield attracts income seekers, but the covered call strategy caps upside potential during tech rallies. Key risks include concentrated exposure to volatile AI/mega-cap stocks and persistent NAV erosion, requiring careful risk-reward assessment for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →
